<DOC>
	<DOCNO>NCT01181271</DOCNO>
	<brief_summary>Relapse remain principle cause treatment failure patient aggressive lymphoma autologous transplantation . Non-myeloablative allogeneic transplantation allow patient receive infusion donor cell attempt induce graft versus lymphoma effect . This study assess feasibility , safety efficacy combination autologous stem cell transplantation follow non-myeloablative transplantation patient poor-risk aggressive lymphoma .</brief_summary>
	<brief_title>Tandem Auto-Allo Transplant Lymphoma</brief_title>
	<detailed_description>This phase II clinical trial investigate feasibility , efficacy sequential autologous stem cell transplant follow non-myeloablative allogeneic transplant patient poor risk lymphoma . Patients enrol onto trial eligible undergo standard high-dose chemotherapy combination busulfan , cyclophosphamide , etoposide follow autologous stem cell transplant . After recovery count clinical status , patient proceed non-myeloablative allogeneic stem cell transplant use fully match relate unrelated donor .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Allopurinol</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Mesna</mesh_term>
	<criteria>Patients highrisk diffuse large B cell transform low grade lymphoma define : Residual disease least 6 cycle anthracyclinebased chemotherapy ( residual disease define persistent bone marrow involvement and/or persistent measurable lymph node solid organ mass PET gallium avid ) Progressive disease least 2 cycle anthracyclinebased chemotherapy Patients initial complete response subsequent relapse within 6 month completion anthracyclinebased chemotherapy Patients Tcell nonHodgkin 's lymphoma define : Peripheral Tcell lymphoma ( ALK negative PTCLU ) include PTCLNOS , HSGD ( hepatosplenic gammadelta TCL ) , AITL ( angioimmunoblastic Tcell lymphoma ) , EATL ( enteropathy associate Tcell lymphoma ) , ALKnegative anaplastic large cell lymphoma Any Tcell histology ( except LGL ) residual disease least 4 cycle anthracyclinebased chemotherapy ( residual disease define persistent bone marrow involvement and/or persistent measurable lymph node solid organ mass PET gallium avid ) Patients mantle cell lymphoma time therapy Patients `` doublehit '' lymphoma characterize presence concurrent overexpression Bcl2 cmyc Patients Hodgkin 's lymphoma Refractory firstline therapy least one second line chemotherapy regimen Relapsed Hodgkin 's lymphoma refractory least one salvage chemotherapy regimen . Patients CLL/SLL 17p cytogenetic abnormality Age 18 year great ECOG performance status 02 Ability understand willingness sign write informed consent document . Responsive disease last therapy determine least one following : At least PR Revised Response Criteria At least PR traditional Cheson Criteria &lt; 10 % overall cellularity involve disease bone marrow biopsy patient involvement bone marrow Minimum 2 x 106 CD34+ cell / kg already collect frozen . These stem cell may collect PBSC pheresis , bone marrow harvest , combination . Patients reevaluate autologous transplant prior proceed nonmyeloablative transplant Pregnancy Evidence HIV infection Heart failure uncontrolled medication ejection fraction le 45 % Active involvement CNS lymphoma Inability provide inform consent Previous autologous allogeneic stem cell transplant Creatinine great 2 gm/dL 24 hour urine creatinine clearance &lt; 50 cc/minute ( satisfy ) Total bilirubin great 2 time upper limit normal except due Gilbert 's syndrome hemolysis . Transaminases great 3 time upper limit normal FVC DLCO le 50 % predict ( DLCO correct hemoglobin level ) Already know posse suitably HLAmatched relate unrelated donor Eligibility proceed allogeneic transplant Can admit allogeneic transplant earlier 40 day later 180 day autologous stem cell transplant . HLA identical ( A , B , C DR ) relate unrelated donor available . HLA type class I loci ( HLA A , B , C ) base complement dependent cytotoxicity assay PCR sequence specific oligonucleotide primer ( SSOP ) . Typing HLA class II ( DRB1 ) base PCR sequence specific oligonucleotide primer ( SSOP ) . No need intravenous hydration previous 2 week Resolved mucositis Renal , cardiac , pulmonary , hepatic function meet standard criterion nonmyeloablative SCT list : Serum Cr &lt; 2 gm/dL LV ejection fraction &gt; 30 % uncontrolled symptom congestive heart failure DLCO &gt; 50 % predict value ( correct hemoglobin ) Transaminases &lt; 5X institution upper limit normal Bilirubin &lt; 3X institution upper limit normal except Gilbert 's Syndrome hemolysis present ECOG PS â‰¤ 2 No intravenous antimicrobial within 2 week No evidence progressive disease , define 25 % increase nadir sum product diameter ( SPD ) lymph node previously identify abnormal prior autologous transplant appearance new lymph node great 1.5 cm great diameter , new bone marrow involvement , new solid organ nodule great 1 cm diameter . This restaging study perform least 28 day autologous transplant within 60 day prior admission allogeneic transplant . Status stable disease ( SD ) acceptable proceed allogeneic transplant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>non-hodgkins lymphoma</keyword>
	<keyword>Hodgkin 's lymphoma</keyword>
	<keyword>Hodgkin 's disease</keyword>
	<keyword>stem cell transplant</keyword>
	<keyword>High-risk diffuse large B cell</keyword>
	<keyword>Transformed low grade lymphoma</keyword>
	<keyword>T-cell non-Hodgkin 's lymphoma</keyword>
	<keyword>Mantle cell lymphoma time therapy</keyword>
	<keyword>`` Double-hit '' lymphoma</keyword>
</DOC>